Clinical Trials Logo

Gastro Esophageal Reflux clinical trials

View clinical trials related to Gastro Esophageal Reflux.

Filter by:

NCT ID: NCT06430047 Recruiting - Clinical trials for Gastro Esophageal Reflux

Efficacy and Safety of EsoDuo®

Start date: November 25, 2022
Phase: Phase 4
Study type: Interventional

Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid

NCT ID: NCT06280664 Recruiting - Clinical trials for Gastro Esophageal Reflux

Efficacy Of Hiatal Closure For GERD

Start date: October 2, 2020
Phase:
Study type: Observational

The purpose of this protocol is to study the efficacy of hiatal closure for early GERD disease. The study team hypothesizes that hiatal closure for early GERD disease is an efficacious treatment of GERD.

NCT ID: NCT06222177 Recruiting - Clinical trials for Gastro Esophageal Reflux

Thresholds of SLR Maneuver in Obese Patients

SLR obese
Start date: January 1, 2024
Phase:
Study type: Observational

There is an increasing interest in High resolution manometry (HRM) in the preoperative assessment of patients with obesity, in order to identify the best surgical option. Sleeve gastrectomy (SG) has been known to increase the risk of gastro-esophageal reflux disease (GERD). Different techniques have been recently developed and validated to offer to these patients protection against pathologic GERD after SG. A recent study found a significant correlation between straight leg raise (SLR) maneuver during HRM and a positive pH-study. However, these maneuver has not been validated in an obese population, therefore the normality cut-off remain unknown. A multicenter study with a large number of patients undergoing pre-operative assessment for bariatric surgery could provide a precise threshold to predict pathologic esophageal acid exposure time.

NCT ID: NCT06025773 Recruiting - Clinical trials for Gastro Esophageal Reflux

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.

NCT ID: NCT05989698 Recruiting - Asthma Clinical Trials

C-mo System 1.0's Validation - Cough Monitoring

C-mo_01
Start date: December 11, 2023
Phase: N/A
Study type: Interventional

Cough is one of the most reported symptoms, especially associated with respiratory diseases. Additionally, cough contains extremely insightful information regarding the patient's health. It is a symptom full of physiopathological information, which can be extremely helpful in clinical practice. However, cough is not currently used as a clinical biomarker given that: 1. Cough is an extremely subjective symptom for patients (patients can't accurately describe and understand their cough's traits). 2. There is currently no tool available to evaluate cough objectively and thoroughly. As such, there is an unmet medical need: solutions for objective cough monitoring and management. C-mo System is a novel non-invasive medical device, which performs an objective monitoring of the patient's cough for long periods of time. The C-mo System consists of a wearable device (C-mo wearable) and a desktop software (C-mo Medical Platform). C-mo System characterises cough automatically through data collection and processing techniques (automatic classification), and its base outputs include: - Cough frequency (how many times the patient coughs) - Cough intensity (how strong cough's expiratory effort is) - Cough type (if the cough is dry, wet, or laryngeal) - Identification of patterns (associations between cough characteristics and specific events, namely the time of day, body position, physical exercising, and meals). It is extremely important to validate C-mo System in a wide and diverse population, given the use of signal processing algorithms and artificial intelligence. C-mo System's base outputs will allow healthcare professionals to improve significantly the medical care associated with this symptom, namely: - Speed-up and improve the accuracy of the diagnosis of several medical conditions, especially respiratory diseases. C-mo System's ability to objectively monitor cough will allow healthcare professionals to make associations between specific cough patterns and specific medical conditions. - Optimize treatment prescription and monitor their effectiveness. C-mo System's objective assessment of cough will allow healthcare professionals to understand if a given therapy is working as intended. - Objectively monitor chronic disease progression. C-mo System's monitoring of cough will allow healthcare professionals to objectively assess the progression of the patient's cough.

NCT ID: NCT05851482 Completed - Clinical trials for Gastro Esophageal Reflux

Validation of HRM Score for the GERD Diagnosis

HRM nomogram
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The goal of this prospective study is to validate a high resolution manometry score to predict pathologic GERD in patients with reflux symptoms. The main question it aims to answer is: Is it possible to predict GERD on high resolution manometry? Participants will be asked to undergo high resolution manometry and pH-study

NCT ID: NCT05760274 Recruiting - Clinical trials for Gastro Esophageal Reflux

Esophageal pH-MII Duration: 12 or 24 Hours?

Start date: July 13, 2022
Phase:
Study type: Observational

To check whether the first 12 hours of MII-pH recording are sufficient to diagnose gastroesophageal reflux disease (GERD) among newborns/infants, with a diagnostic accuracy similar to 24 hours of recording as currently advised.

NCT ID: NCT05689918 Active, not recruiting - Clinical trials for Gastro Esophageal Reflux

Gastroesophageal Reflux Disease in the Dutch Population

REFLUX
Start date: December 7, 2022
Phase:
Study type: Observational [Patient Registry]

Rationale: Screening for esophageal adenocarcinoma (EAC) precursors and treating them may help to decrease mortality of this malignancy. To understand the size of the target population for potential EAC screening, insight in the prevalence of registered and unregistered individuals with gastro-esophageal reflux disease (GERD) symptoms is needed. Insight in public awareness of EAC will provide additional useful information for public communication strategies. Objective: The aims of this study are to assess the prevalence of GERD symptoms and related help-seeking behavior, registered and unregistered medication use and awareness of esophageal cancer in the general Dutch population. Study design: Cross-sectional population-based survey. Study population: Dutch citizens aged 18-75 years. Methods: Eligible individuals will be selected from the Dutch population registry (BRP) using simple random sampling. Invitations will be sent by postal mail with participants being directed to a digital survey. Main study parameters/endpoints: The outcome variables are presence of current GERD symptoms, number of GERD patients that consulted a doctor, number of GERD patients using prescribed and/or over the counter (OTC) antacids, histamine-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), and awareness and beliefs about esophageal cancer. The association between socio-demographic background and outcome variables will also be evaluated. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects will not directly benefit from participating in this study. Nonetheless, participating in this study is not associated with any healthcare risks and the burden for the subjects is very low. The survey has a low burdensome nature and will take approximately 20 minutes to complete. All data will be pseudonymized, refusal to fill out the survey or desire to withdraw from the study will not have any consequences for the invited subject.

NCT ID: NCT05579444 Terminated - Obesity Clinical Trials

Systems Biology of Gastrointestinal and Related Diseases

Start date: November 11, 2022
Phase:
Study type: Observational

This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and remissions, or progression of their disease.

NCT ID: NCT05570448 Recruiting - Clinical trials for Gastro Esophageal Reflux

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

AREA21
Start date: February 15, 2022
Phase: N/A
Study type: Interventional

This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months. Patients must have a positive pH test and a negative manometry (no treatment) procedure.